Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
| Total | Transactions | Amount |
| Buys | 30 | $21,240,602 |
| Sells | 25 | $16,116,188 |
| Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
| 22 Nov 2024 16:03 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 19 Nov 2024 | Purchase | 34,843 | 14.2269 | 495,708 | I |
| 22 Nov 2024 16:03 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 19 Nov 2024 | Purchase | 34,843 | 14.2269 | 495,708 | I |
| 22 Nov 2024 16:03 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 20 Nov 2024 | Purchase | 18,750 | 14.1921 | 266,102 | I |
| 22 Nov 2024 16:03 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 20 Nov 2024 | Purchase | 18,750 | 14.1921 | 266,102 | I |
| 07 Oct 2024 16:34 | INBX | Inhibrx Biosciences Inc | VUORI KRISTIINA MD | Director | 03 Oct 2024 | Purchase | 6,667 | 15 | 100,005 | D |
| 16 Sep 2024 17:12 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 16 Sep 2024 | Purchase | 13,037 | 17.13 | 223,324 | I |
| 16 Sep 2024 17:12 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 12 Sep 2024 | Purchase | 26,963 | 15.05 | 405,793 | I |
| 12 Sep 2024 17:14 | INBX | Inhibrx Biosciences Inc | VUORI KRISTIINA MD | Director | 11 Sep 2024 | Purchase | 6,457 | 15.07 | 97,307 | D |
| 12 Sep 2024 17:14 | INBX | Inhibrx Biosciences Inc | VUORI KRISTIINA MD | Director | 10 Sep 2024 | Purchase | 179 | 15 | 2,685 | D |
| 10 Sep 2024 17:00 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 10 Sep 2024 | Purchase | 8,500 | 15.19 | 129,115 | I |
| 10 Sep 2024 17:00 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 09 Sep 2024 | Purchase | 9,500 | 15.21 | 144,495 | I |
| 10 Sep 2024 17:00 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 06 Sep 2024 | Purchase | 26,000 | 15.29 | 397,540 | I |
| 03 Sep 2024 17:31 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 03 Sep 2024 | Purchase | 4,712 | 16.31 | 76,853 | I |
| 03 Sep 2024 17:31 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 03 Sep 2024 | Purchase | 15,288 | 15.66 | 239,410 | I |
| 03 Sep 2024 17:31 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 30 Aug 2024 | Purchase | 10,000 | 14.02 | 140,200 | I |
| 03 Sep 2024 17:31 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 29 Aug 2024 | Purchase | 10,000 | 14.03 | 140,300 | I |
| 03 Sep 2024 16:27 | INBX | Inhibrx Biosciences Inc | VUORI KRISTIINA MD | Director | 29 Aug 2024 | Purchase | 7,140 | 14 | 99,960 | D |
| 30 Aug 2024 16:16 | INBX | Inhibrx Biosciences Inc | MANHARD KIMBERLY | Director | 28 Aug 2024 | Purchase | 10,000 | 13.98 | 139,800 | I |
| 26 Aug 2024 16:26 | INBX | Inhibrx Biosciences Inc | FORSYTH DOUGLAS | Director | 23 Aug 2024 | Purchase | 59,812 | 14.07 | 841,555 | I |
| 26 Aug 2024 16:26 | INBX | Inhibrx Biosciences Inc | FORSYTH DOUGLAS | Director | 22 Aug 2024 | Purchase | 15,188 | 12.89 | 195,773 | I |
| 22 Aug 2024 16:29 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 21 Aug 2024 | Purchase | 12,945 | 12.93 | 167,379 | I |
| 22 Aug 2024 16:29 | INBX | Inhibrx Biosciences Inc | LAPPE MARK | Chief Executive Officer | 20 Aug 2024 | Purchase | 27,055 | 12.97 | 350,903 | I |
| 07 Jun 2024 18:05 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 05 Jun 2024 | Purchase | 49,284 | 17.23 | 849,163 | I |
| 07 Jun 2024 18:05 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 05 Jun 2024 | Purchase | 8,265 | 17.89 | 147,861 | I |
| 04 Jun 2024 17:27 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 04 Jun 2024 | Purchase | 23,726 | 18.24 | 432,762 | I |
| 04 Jun 2024 17:27 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 04 Jun 2024 | Purchase | 65,337 | 17.44 | 1,139,477 | I |
| 04 Jun 2024 17:27 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 03 Jun 2024 | Purchase | 80,738 | 17.9 | 1,445,210 | I |
| 04 Jun 2024 17:27 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 03 Jun 2024 | Purchase | 46,792 | 16.61 | 777,215 | I |
| 04 Jun 2024 17:27 | INBX | Inhibrx Biosciences Inc | KAYYEM JON FAIZ | Director | 31 May 2024 | Purchase | 70,193 | 16.14 | 1,132,915 | I |
| 30 May 2024 18:21 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 28 May 2024 | Sale | 300,000 | 34.3 | 10,290,000 | I |
| 30 Aug 2023 20:44 | INBX | Inhibrx Inc | VIKING GLOBAL INVESTORS LP | 10% | 28 Aug 2023 | Purchase | 511,627 | 19.35 | 9,899,982 | I |
| 02 Mar 2023 16:17 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 01 Mar 2023 | Sale | 400 | 24.7075 | 9,883 | I |
| 02 Mar 2023 16:17 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 01 Mar 2023 | Sale | 39,600 | 24.2007 | 958,348 | I |
| 01 Mar 2023 16:41 | INBX | Inhibrx Inc | LAPPE MARK | Chief Executive Officer | 28 Feb 2023 | Sale | 60 | 25.0208 | 1,501 | I |
| 02 Feb 2023 19:26 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 02 Feb 2023 | Sale | 1,130 | 25.8947 | 29,261 | I |
| 02 Feb 2023 19:26 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 02 Feb 2023 | Sale | 10,120 | 25.4045 | 257,094 | I |
| 02 Feb 2023 19:26 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 01 Feb 2023 | Sale | 693 | 25.6567 | 17,780 | I |
| 02 Feb 2023 19:26 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 01 Feb 2023 | Sale | 14,608 | 25.0798 | 366,366 | I |
| 02 Feb 2023 19:26 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 01 Feb 2023 | Sale | 13,449 | 24.2925 | 326,710 | I |
| 24 Jan 2023 18:46 | INBX | Inhibrx Inc | LAPPE MARK | Chief Executive Officer | 24 Jan 2023 | Sale | 63 | 26.1127 | 1,645 | I |
| 24 Jan 2023 18:46 | INBX | Inhibrx Inc | LAPPE MARK | Chief Executive Officer | 24 Jan 2023 | Sale | 4,272 | 25.71 | 109,833 | I |
| 24 Jan 2023 18:46 | INBX | Inhibrx Inc | LAPPE MARK | Chief Executive Officer | 23 Jan 2023 | Sale | 21,665 | 25.3572 | 549,364 | I |
| 23 Jan 2023 18:10 | INBX | Inhibrx Inc | KAYYEM JON FAIZ | Director | 23 Jan 2023 | Sale | 9,500 | 25.2631 | 239,999 | I |
| 04 Jan 2023 17:53 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 04 Jan 2023 | Sale | 3,003 | 23.9903 | 72,043 | I |
| 04 Jan 2023 17:53 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 04 Jan 2023 | Sale | 4,102 | 23.1072 | 94,786 | I |
| 04 Jan 2023 17:53 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 03 Jan 2023 | Sale | 2,084 | 25.0927 | 52,293 | I |
| 04 Jan 2023 17:53 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 03 Jan 2023 | Sale | 8,598 | 24.3575 | 209,426 | I |
| 04 Jan 2023 17:53 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 03 Jan 2023 | Sale | 22,213 | 23.412 | 520,051 | I |
| 22 Dec 2022 16:04 | INBX | Inhibrx Inc | KAYYEM JON FAIZ | Director | 21 Dec 2022 | Sale | 1,959 | 27.6099 | 54,088 | I |
| 22 Dec 2022 16:04 | INBX | Inhibrx Inc | KAYYEM JON FAIZ | Director | 21 Dec 2022 | Sale | 7,541 | 26.8653 | 202,591 | I |
| 20 Dec 2022 16:59 | INBX | Inhibrx Inc | LAPPE MARK | Chief Executive Officer | 19 Dec 2022 | Sale | 754 | 26.2859 | 19,820 | I |
| 20 Dec 2022 16:59 | INBX | Inhibrx Inc | LAPPE MARK | Chief Executive Officer | 19 Dec 2022 | Sale | 25,246 | 25.5337 | 644,624 | I |
| 07 Dec 2022 16:30 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 06 Dec 2022 | Sale | 1,392 | 28.4608 | 39,617 | I |
| 07 Dec 2022 16:30 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 06 Dec 2022 | Sale | 17,681 | 27.5716 | 487,493 | I |
| 07 Dec 2022 16:30 | INBX | Inhibrx Inc | ECKELMAN BRENDAN P. | Chief Scientific Officer | 06 Dec 2022 | Sale | 20,927 | 26.8348 | 561,572 | I |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)